Long-term effectiveness of pentavalent and monovalent rotavirus vaccines against hospitalization in Taiwan children
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Two rotavirus vaccines (RV1 and RV5) are available on the private market in Taiwan, not included in national immunization program. Scanty reports evaluated the rotavirus vaccine effectiveness (VE) in Asian countries.
METHODS: From February 2014-July 2017, we conducted a prospective case-control study in ten hospitals in Taiwan. Case-patients included children aged 8-59 months, and hospitalized with laboratory-confirmed rotavirus acute gastroenteritis (AGE). For each case patient, up to four controls, rotavirus-negative AGE or non-AGE illnesses, respectively, were matched by gender, age and enrolled date. Vaccination history was confirmed through vaccination card or hospital record. VE was calculated as (1 - odds ratio of vaccination) × 100%.
RESULTS: Totally 4248 AGE patients and 2242 non-AGE controls were enrolled. A total of 330 case-patients with rotavirus AGE, 1226 rotavirus-negative AGE controls and 1122 non-AGE controls were included for analysis. Unvaccinated rate was 85.15% for rotavirus-positive cases, 42.9% for rotavirus-negative controls, and 34.31% for non-AGE controls. VE of two-dose RV1 was 84.9% (95% confidence interval [CI]:77.7%, 90.1%) for rotavirus-negative AGE and 88.9% (95% CI: 83.4%, 92.8%) for non-AGE controls, while VE of three-dose RV5 was 92.5% (95% CI: 85.1%, 96.7%) and 96.4% (95% CI: 91.9%, 98.6%), respectively. For respective vaccine, VEs were not significantly different in term of rotavirus genotypes. VEs of both vaccines declined <80% in children aged three years by combined controls.
CONCLUSIONS: Both vaccines provided excellent and sustained protection against rotavirus AGE hospitalization in children in Taiwan, but the effectiveness declined slightly in children aged three years.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Vaccine - 38(2020), 41 vom: 22. Sept., Seite 6435-6441 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huang, Yhu-Chering [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case-control |
|---|
| Anmerkungen: |
Date Completed 27.04.2021 Date Revised 27.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2020.07.067 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313433666 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313433666 | ||
| 003 | DE-627 | ||
| 005 | 20231225150548.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2020.07.067 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1044.xml |
| 035 | |a (DE-627)NLM313433666 | ||
| 035 | |a (NLM)32768335 | ||
| 035 | |a (PII)S0264-410X(20)31011-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huang, Yhu-Chering |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term effectiveness of pentavalent and monovalent rotavirus vaccines against hospitalization in Taiwan children |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.04.2021 | ||
| 500 | |a Date Revised 27.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Two rotavirus vaccines (RV1 and RV5) are available on the private market in Taiwan, not included in national immunization program. Scanty reports evaluated the rotavirus vaccine effectiveness (VE) in Asian countries | ||
| 520 | |a METHODS: From February 2014-July 2017, we conducted a prospective case-control study in ten hospitals in Taiwan. Case-patients included children aged 8-59 months, and hospitalized with laboratory-confirmed rotavirus acute gastroenteritis (AGE). For each case patient, up to four controls, rotavirus-negative AGE or non-AGE illnesses, respectively, were matched by gender, age and enrolled date. Vaccination history was confirmed through vaccination card or hospital record. VE was calculated as (1 - odds ratio of vaccination) × 100% | ||
| 520 | |a RESULTS: Totally 4248 AGE patients and 2242 non-AGE controls were enrolled. A total of 330 case-patients with rotavirus AGE, 1226 rotavirus-negative AGE controls and 1122 non-AGE controls were included for analysis. Unvaccinated rate was 85.15% for rotavirus-positive cases, 42.9% for rotavirus-negative controls, and 34.31% for non-AGE controls. VE of two-dose RV1 was 84.9% (95% confidence interval [CI]:77.7%, 90.1%) for rotavirus-negative AGE and 88.9% (95% CI: 83.4%, 92.8%) for non-AGE controls, while VE of three-dose RV5 was 92.5% (95% CI: 85.1%, 96.7%) and 96.4% (95% CI: 91.9%, 98.6%), respectively. For respective vaccine, VEs were not significantly different in term of rotavirus genotypes. VEs of both vaccines declined <80% in children aged three years by combined controls | ||
| 520 | |a CONCLUSIONS: Both vaccines provided excellent and sustained protection against rotavirus AGE hospitalization in children in Taiwan, but the effectiveness declined slightly in children aged three years | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Case-control | |
| 650 | 4 | |a Rotavirus | |
| 650 | 4 | |a Rotavirus vaccine | |
| 650 | 4 | |a Taiwan | |
| 650 | 4 | |a Vaccine effectiveness | |
| 650 | 7 | |a Rotavirus Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Attenuated |2 NLM | |
| 700 | 1 | |a Wu, Fang-Tzy |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yi-Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ching-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Chun-Yi-Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Hsiao-Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chi, Hsin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Li-Min |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Yu-Huai |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jian-Te |e verfasserin |4 aut | |
| 700 | 1 | |a Shih, Shu-Man |e verfasserin |4 aut | |
| 700 | 1 | |a Ching-Yi-Huang |e verfasserin |4 aut | |
| 700 | 1 | |a Hsiung, Chao A |e verfasserin |4 aut | |
| 700 | 0 | |a Taiwan Pediatric Infectious Disease Alliance |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 38(2020), 41 vom: 22. Sept., Seite 6435-6441 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2020 |g number:41 |g day:22 |g month:09 |g pages:6435-6441 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2020.07.067 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2020 |e 41 |b 22 |c 09 |h 6435-6441 | ||